OptiNose US, Inc., Yardley, PA. RATIONALE: Intranasal steroids, usually by inhalation (INS), are firstline therapy for chronic rhinosinusitis, but most patients are frustrated with treatment efficacy. We compare patient satisfaction and ease-of-use with INS vs an exhalation delivery system (EDS-FLU; XHANCEä), that can help achieve better superior/posterior drug deposition. METHODS: Analysis of ease-of-use and comfort in two 24-week (16 double-blind+8 open-label; N5322/321) RCTs with EDS-FLU in patients with CRS with nasal polyps. Patients reported current (or most recent) prescription intranasal steroid at screening and compared to EDS-FLU at weeks 4, 16, and 24. Self-reported ''real world'' survey results from patients prescribed EDS-FLU outside clinical trials were also evaluated. RESULTS: In the RCTs, at screening, 77-84% and 71-74% of patients reported their current/most recent inhaled INS was easy-to-use and comfortable-to-use, respectively. At weeks 4, 16, and 24, 86-88%, 87-91%, and 90% reported EDS-FLU was easy-to-use and 80-85%, 82-88%, and 83-85%, reported it was comfortable to use, respectively. Compared to their current/most recent inhaled nasal steroid, at 4 weeks, EDS-FLU patients reported less loss of drug to drip down the back of the throat (61-67.0%) or out the front of the nose (55-64%). In a ''real world'' patient survey (N52733), 89% of patients electing to complete the survey reported treatment satisfaction and 77% preferred EDS-FLU to prior inhaled steroids or steroid rinses. CONCLUSIONS: Large RCTs and a large survey of 'real-world' patients suggest that patients find EDS-FLU easy-to-use, comfortable, and associated with improved symptoms and high patient satisfaction. Inflamax Research Limited, Mississauga, Canada. RATIONALE: Non-Allergic Rhinitis (NAR) has been estimated to affect 17 million Americans annually. Few therapeutic studies have been conducted on well-characterized patients with NAR. Alternative therapies have been proposed but have ineffective for the treatment of NAR conditions. Studies have demonstrated topical capsaicin is effective at reducing nasal congestion and discharge in allergic and NAR. The aim of this work was to further assess the onset of action and benefits of capsaicin in NAR. METHODS: A total of 46 subjects with NAR and negative skin prick test were enrolled in this study. Subjects received capsaicin or placebo (23 per arm) 1-2 sprays/nostril twice daily to maximum of 8 total sprays/day for 14 days. Subjects recorded their instantaneous and reflective nasal symptoms (TNSS) using an electronic diary (ePDAT Ò ). Time of first relief of symptoms were measured by patients using a stopwatch. RESULTS: TNSS significantly improved from as early as 10 minutes post dosing in the capsaicin treatment group versus placebo. This improvement was sustainable until 60 minute time-point. It was observed that the majority of subjects treated with capsaicin (12/23) 52.2%, showed relief under one minute and (17/23) 74.0% of patients showed relief for all the symptoms under 2 minutes from time of first-dosing. CONCLUSIONS: Capsaicin Nasal Spray showed significant rapid and sustainable relief in overall composite symptom scores of TNSS. The Nasal Spray was generally well-tolerated and there were no safety concerns raised during the study. This finding corroborates and confirms the nasal symptom results from a previous study with the same product.
